Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop

Leukemia Research

Volumn 36, Issue 3, 2012, Pages 264-270

  Platzbecker, Uwe ^a   Santini, Valeria ^b   Mufti, Ghulam J ^c   Haferlach, Claudia ^d   Maciejewski, Jaroslaw P ^e   Park, Sophie ^f,g   Solé, Francesc ^h   van De Loosdrecht, Arjan A ⁱ   Haase, Detlef ^j  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF FLORENCE   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^e TAUSSIG CANCER INSTITUTE   (United States)

^f Université ^*  (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h HOSPITAL DEL MAR   (Spain)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF GÖTTINGEN   (Germany)

more..

Author keywords

Diagnosis; MDS; Prognosis

Indexed keywords

AZACITIDINE; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; CHROMOSOME ANALYSIS; CONSENSUS DEVELOPMENT; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG RESPONSE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKOCYTE DIFFERENTIAL COUNT; MICROARRAY ANALYSIS; MYELODYSPLASTIC SYNDROME; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

CONSENSUS; DISEASE MANAGEMENT; GUIDELINES AS TOPIC; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84855982156     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.11.005     Document Type: Article

References (49)

1. Malcovati L., Nimer S.D. Myelodysplastic syndromes: diagnosis and staging. Cancer Control 2008, 15(Suppl.):4-13.
2. Bacher U., Haferlach T., Kern W., Weiss T., Schnittger S., Haferlach C. The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes. Cancer 2009, 115:4524-4532.
3. Catenacci D.V., Schiller G.J. Myelodysplasic syndromes: a comprehensive review. Blood Rev 2005, 19:301-319.
4. Komrokji R.S., Bennett J.M. Evolving classifications of the myelodysplastic syndromes. Curr Opin Hematol 2007, 14:98-105.
5. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
6. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
7. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
8. Sloand E.M., Wu C.O., Greenberg P., Young N., Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008, 26:2505-2511.
9. Haase D., Germing U., Schanz J., Pfeilstocker M., Nosslinger T., Hildebrandt B., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
10. Schanz J., Tüchler F., Sole F., Mallo M., Hildebrandt B., Slovak M., et al. Proposal of a new, comprehensive cytogenetic scoring system for primary MDS. Haematologica 2010, 95(Suppl. 2):219. [Abstract 0535].
11. Tricot G., Boogaerts M.A., De Wolf-Peeters C., Van den Berghe H., Verwilghen R.L. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br J Haematol 1985, 59:659-670.
12. Valent P., Horny H.P., Bennett J.M., Fonatsch C., Germing U., Greenberg P., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007, 31:727-736.
13. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
14. Santini V., Alessandrino P.E., Angelucci E., Barosi G., Billio A., Di M.M., et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res 2010, 34:1576-1588.
15. Valent P., Orazi A., Busche G., Schmitt-Graff A., George T.I., Sotlar K., et al. Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget 2010, 1:483-496.
16. Steidl C., Steffens R., Gassmann W., Hildebrandt B., Hilgers R., Germing U., et al. Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. Leuk Res 2005, 29:987-993.
17. Braulke F., Schanz J., Jung K., Shirneshan K., Schulte K., Schuetze C., et al. FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. Leuk Res 2010, 34:1296-1301.
18. Galvan A.B., Mallo M., Arenillas L., Salido M., Espinet B., Pedro C., et al. Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia?. Leuk Res 2010, 34:1242-1245.
19. Mallo M., Arenillas L., Espinet B., Salido M., Hernandez J.M., Lumbreras E., et al. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-Haematologica 2008, 93:1001-1008.
20. Cherry A.M., Slovak M.L., Campbell L.J., Chun K., Eclache V., Haase D., et al. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) on myelodysplasia? An international study comparing cytogenetics and interphase FISH using parallel PB and BM samples. Blood 2010, 116. [Abstract 2922].
21. Gohring G., Giagounidis A., Busche G., Hofmann W., Kreipe H.H., Fenaux P., et al. Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide. Haematologica 2011, 96:319-322.
22. Braulke F., Schanz J., Detken S., Seraphin J., Metz M., Brümmerdörf T., et al. Detection of rare abnormalities and karyotype evolution in MDS patients from peripheral blood: first results from The Mulitcenter German Prospective Diagnostic CD34+FISH-Study. Haematologica 2010, 95:219. [Abstract 0536].
23. van de Loosdrecht A.A., Westers T.M., Westra A.H., Drager A.M., van der Velden V.H., Ossenkoppele G.J. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008, 111:1067-1077.
24. van de Loosdrecht A.A., Alhan C., Bene M.C., la Porta M.G., Drager A.M., Feuillard J., et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009, 94:1124-1134.
25. Wells D.A., Benesch M., Loken M.R., Vallejo C., Myerson D., Leisenring W.M., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003, 102:394-403.
26. Scott B.L., Wells D.A., Loken M.R., Myerson D., Leisenring W.M., Deeg H.J. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 2008, 112:2681-2686.
27. Westers T.M., Alhan C., Chamuleau M.E., van der Vorst M.J., Eeltink C., Ossenkoppele G.J., et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 2010, 115:1779-1784.
28. Alhan C., Westers T.M., Eeltink C., Cali C., Ossenkoppele G.J., Van de Loosdrecht A.A. Flow cytometric score correlates with clinical response to azacitidine in intermediate-2 and high risk myelodysplastic syndrome patients. Blood 2010, 116. [Abstract 441].
29. Maciejewski J.P., Mufti G.J. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 2008, 112:965-974.
30. Mohamedali A., Gaken J., Twine N.A., Ingram W., Westwood N., Lea N.C., et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007, 110:3365-3373.
31. Gondek L.P., Tiu R., O'Keefe C.L., Sekeres M.A., Theil K.S., Maciejewski J.P. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008, 111:1534-1542.
32. Mohamedali A.M., Smith A.E., Gaken J., Lea N.C., Mian S.A., Westwood N.B., et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009, 27:4002-4006.
33. Delhommeau F., Dupont S., Della V.V., James C., Trannoy S., Masse A., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
34. Langemeijer S.M., Kuiper R.P., Berends M., Knops R., Aslanyan M.G., Massop M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41:838-842.
35. Gelsi-Boyer V., Trouplin V., Adelaide J., Bonansea J., Cervera N., Carbuccia N., et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009, 145:788-800.
36. Nikoloski G., Langemeijer S.M., Kuiper R.P., Knops R., Massop M., Tonnissen E.R., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010, 42:665-667.
37. Garcia-Manero G. Prognosis of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2010 2010, 330-337.
38. Kulasekararaj A.G., Mohamedali A.M., Smith A.E., Lea N.C., Kizilors A., Abdallah A., et al. Polycomb complex group gene mutations and their prognostic relevance in 5-azacitidine treated myelodysplastic syndrome patients. Blood 2010, 116. [Abstract 125].
39. Jadersten M., Saft L., Pellagatti A., Gohring G., Wainscoat J.S., Boultwood J., et al. Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 2009, 94:1762-1766.
40. Itzykson R., Kosmider O., Cluzeau T., Mansat-De M.V., Dreyfus F., Beyne-Rauzy O., et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011, April 15 [Epub ahead of print].
41. Smith A.E., Mohamedali A.M., Kulasekararaj A., Lim Z., Gaken J., Lea N.C., et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010, 116:3923-3932.
42. Mills K.I., Kohlmann A., Williams P.M., Wieczorek L., Liu W.M., Li R., et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 2009, 114:1063-1072.
43. Malcovati L., Germing U., Kuendgen A., la Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
44. Gale R.P., Barosi G., Barbui T., Cervantes F., Dohner K., Dupriez B., et al. What are RBC-transfusion-dependence and -independence?. Leuk Res 2011, 35:8-11.
45. Malcovati L., la Porta M.G., Strupp C., Ambaglio I., Kuendgen A., Nachtkamp K., et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011, June 9 [Epub ahead of print].
46. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
47. Greenberg P., Tuechler H., Schanz J., et al. Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (lWG-PM). Leuk Res 2011, 35:S6.
48. Bernasconi P., Klersy C., Boni M., Dambruoso I., Zappatore R., Cavigliano P., et al. The International Multicentric Cooperation cytogenetic scoring system effectively predicts disease outcome in de novo MDS. Haematologica 2011, 96(S2):99.
49. Makishima H., Rataul M., Gondek L.P., Huh J., Cook J.R., Theil K.S., et al. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). Leuk Res 2010, 34:447-453.